Monoclonal Antibody
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
48
NCT06101823
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 25, 2023
Completion: Jun 30, 2025
Loading map...